TCXB

10.2901.06%
MT

Michael Thomas Henderson

Independent Director

Dr. Michael Thomas Henderson, MD, is Independent Director of TCGX Acquisition Corp. II from October 15, 2026. Dr. Henderson served as Chief Executive Officer at Apogee Therapeutics, Inc. since September 2022 until September 3, 2026 and was its Director since June 2023 until September 3, 2026. He had been Chief Business Officer of BridgeBio Pharma, Inc. since January 2020 until 2022 and served as its Senior Vice President of Asset Acquisition, Strategy and Operations since December 2017 until 2020. Dr. Henderson serves as Independent Director at Spyre Therapeutics, Inc. (formerly known as Aeglea BioTherapeutics, Inc.) since June 2023. Dr. Henderson joined BridgeBio as Vice President of Asset Acquisition, Strategy and Operations in April 2016. Dr. Henderson serves as the Chief Business Officer of certain of subsidiaries, QED Therapeutics, Inc. and Origin Biosciences, Inc. since December 2017 and June 2018, respectively. Dr. Henderson also serves on the board of directors for certain of subsidiaries, including Quartz Therapeutics, Inc. since September 2016, TheRas, Inc. since September 2016 and Adrenas Therapeutics, Inc. since July 2017. Prior to BridgeBio, Dr. Henderson worked as a Senior Associate at McKinsey & Company from January 2015 to April 2016 and prior to that, he co-founded PellePharm, Inc. in August 2011. Dr. Henderson served as an Independent Director at ARYA Sciences Acquisition Corp IV since February 2021 until July 2024. Dr. Henderson received his B.A. with high honors in global health with a citation in Spanish from Harvard University and his M.D. with a scholarly concentration in health services and policy from Stanford University where he was a member of both the Ignite and Leadership in Health Disparities Programs.has B.A. from Harvard University. Dr. Henderson has M.D. from Stanford University.

Positions